InvestorsHub Logo
Followers 229
Posts 21458
Boards Moderated 2
Alias Born 08/03/2006

Re: BooDog post# 671

Wednesday, 12/16/2020 4:28:15 PM

Wednesday, December 16, 2020 4:28:15 PM

Post# of 769
Here's the science with AC Bioscience. They just may move this along smartly.

https://www.ac-bioscience.com/pipeline#ja-section-545

https://finance.yahoo.com/news/lexicon-pharmaceuticals-enters-data-collaboration-210500959.html

Message in reply to:

Lexicon Pharmaceuticals Enters Data Collaboration With AC Bioscience
4:05 pm ET December 16, 2020 (Globe Newswire) Print
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has entered a collaboration enabling the use by AC Bioscience LTD of preclinical and clinical data for LX2931 without granting any right or license under any of Lexicon's patent rights for the compound. LX2931 is a small molecule sphingosine-1-phosphate (S1P) lyase inhibitor that is currently not in active development at Lexicon.

"In line with our realignment around the rapid development of the LX9211 program, we continue to evaluate our pipeline and determine the most effective way to advance our broad library of compounds and targets," said Praveen Tyle, Ph.D., executive vice president of research and development. "We are pleased to collaborate with AC Bioscience to accelerate their efforts around S1P and look forward to learning additional information about this potentially interesting pathway."

Under the terms of the agreement, Lexicon will receive an upfront payment and is eligible to receive milestone payments totaling up to $5.3 million in the aggregate.

About Lexicon Pharmaceuticals



Do your research! Play the TA. All posts are my opinion.
Is fundamental trading dead?

"We hope not." Richard Dennis

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent LXRX News